Press releases

ORYZON receives “Intention to grant” communication for patent relating to the use of vafidemstat in Borderline Personality Disorder

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in first-line acute myeloid leukemia

ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decision to grant” communications

ORYZON to provide corporate progress updates at several events in September

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

ORYZON receives “Decision to grant” for two important patents for vafidemstat in Japan

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

ORYZON announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb trial in Borderline Personality Disorder, at the 37th ECNP annual conference

ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut AML patients at EHA-2024

ORYZON announces journal publication of final Phase IIa ALICE results with iadademstat in The Lancet Haematology